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Abstract
C-C chemokine receptor 7 (CCR7) controls lymphocyte migration to secondary lymphoid organs. Although CCR7 has
been implicated in targeting the metastasis of cancers to lymph nodes, the role of CCR7 in the metastasis of breast
cancer, along with the molecular mechanisms that are controlled by CCR7 that target breast cancer metastasis to the
lymph nodes, has yet to be defined. To explore the cellular and molecular mechanisms of breast cancer cell migration
to the lymph nodes, we used the mouse MMTV-PyVmT mammary tumor cells (PyVmT) transfected with CCR7 and
the human CCR7-expressing MCF10A and MCF7 mammary cell lines. We found that the CCR7 ligands CCL19 and
CCL21, controlled cell migration using the β1-integrin heterodimeric adhesion molecules. To define a physiological
significance for CCR7 regulation of migration, we used the FVB syngeneic mouse model of metastatic breast cancer.
When CCR7-negative PyVmT cells transfected with control vector were orthotopically transferred to the mammary
fat pad of FVB mice, tumors metastasized to the lungs (10/10 mice) but not to the lymph nodes (0/10). In contrast,
CCR7-expressing PyVmT (CCR7-PyVmT) cells metastasized to the lymph nodes (6/10 mice) and had a reduced rate
of metastasis to the lungs (4/10 mice). CCR7-PyVmT tumors grew significantly faster than PyVmT tumors, which
mirrored the growth in vitro, of CCR7-PyVmT, MCF7, and MCF10A mammospheres. This model provides tools for
studying lymph node metastasis, CCR7 regulation of tumor cell growth, and targeting of breast cancer cells to the
lymph nodes.
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Introduction
When a breast tumor has metastasized to more than four lymph nodes,
a woman’s chance of surviving breast cancer is significantly reduced.
Consequently, clinical staging of breast cancer involves determining
whether breast tumors have metastasized to the lymph nodes. There-
fore, it is puzzling that there is a subset of women with metastasis to the
lymph nodes that are long-term breast cancer survivors. Whereas few
molecular mechanisms that target breast tumor metastasis to the lymph
nodes have been defined, recently, it was found that C-C chemokine
receptor 7 (CCR7), which responds to small (8-12 kDa) chemotactic
cytokines, is expressed in breast tumor metastases [1]. In these patients,
CCR7-expressing metastases were more likely to be found in surgically
removable lymphoid tissue than in visceral tissues [2]. In contrast, co-
expression of the epidermal growth factor receptor (EGFR) with CCR7
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with breast cancer has been linked with a poor prognosis [1]. Because
an animal model of CCR7-expressing tumors, which mirrors what has
been observed clinically, has yet to be developed, the roles of CCR7 in
disease progression and in breast cancer metastasis to the lymphoid tis-
sues and other organs remain controversial.
CCR7 is activated by binding to two chemokines, CCL19 and CCL21
[3,4]. Under normal circumstances, naive T cells use CCL21 to enter
lymphoid tissues from the blood throughhigh endothelial venules and into
the T-cell zones before returning to circulation. T cells are activated by
CCL19, which is expressed by mature dendritic cells [5]. Consequently,
CCL19 and CCL21 are important for the coordination of the adaptive
immune responses between dendritic cells, B cells, and T cells, and these
ligands function as critical mediators of the inflammatory response.
Therefore, it is likely that chemotaxis of CCR7-expressing tumors to
CCL19 or CCL21may contribute to tumor cell lymph node localization.
It is thought that metastasis results from nonrandom events where
tumor cells target organs in response to unique factors found within the
targeted organ [6]. These factors are thought to contribute to tumor
cell adhesion, migration, organ invasion, and growth. During metasta-
sis, a tumor cell must detach from the primary tumor, rearrange shape,
and extravasate through the microvessel walls to migrate to the target
tissue. CCR7 regulates T-cell migration, which makes it important to
understand its role during breast tumor metastasis.
CCR7 is upregulated in certain breast cancers [7]. To understand the
role of CCR7 up-regulation, we initially examined the levels of CCR7
expressed in fresh human breast cancer tissues. We adapted a mouse
mammary tumor virus (MMTV)–polyoma virus middle T antigen
(PyVmT) model of metastatic breast cancer to express low levels of
CCR7 similar to those found in humans and to study the role of
CCR7 in breast cancer progression andmetastasis. In thismodel, PyVmT
cells orthotopically transplanted to the mammary fat pads preferentially
metastasize to the lungs [8].We expressedCCR7 in PyVmT cells to allow
us to determine the role for CCR7 in breast cancer progression and me-
tastasis. In vivo, we found that CCR7 directs the migration of metastasis
to the lymph nodes, in preference to the lung, the site where CCR7 (−)
PyVmT cells metastasize. To define the mechanisms used by tumors to
metastasize, we used in vitro studies. In vitro, we examined the ability of
PyVmTtumor cells to grow in the presence of lung and lymphnode tissues
using mammosphere cultures. We observed that whereas CCR7 (−)
PyVmTmammospheres grow at equivalent rates in the presence of lung
and lymph nodes, CCR7-expressing PyVmTmammospheres grow prefer-
entially in the presence of lymph node tissues. To identify the mechanisms
used by CCR7-expressing PyVmT to grow in the lymph nodes, we exam-
ined the role of CCR7 ligands in controlling cell spread and proliferation,
the essential steps in cell migration and survival.We found that similar to its
role in lymphocytes, CCR7 promotes cell spread andmigration of PyVmT
cells transfectedwithCCR7 aswell as inCCR7(+) human breast cancer cell
lines. In addition, we found that, in both in vivo and in three-dimensional
in vitro culture,CCR7-expressing tumors growmore rapidly in the presence
of CCL19 or CCL21 compared with untreated controls. Taken together,
these studies define a newmodel that can be used to study lymph node
metastasis and describe chemokine receptor–regulated mechanisms used
by breast cancer cells to successfully metastasize to the lymph nodes.
Materials and Methods
Chemicals and Reagents
Chemicals and reagents were purchased unless otherwise specified.
The following antibodies were purchased: M2 (anti-FLAG; Sigma,
St Louis, MO), fluorescein-conjugated antimouse ( Jackson Immunore-
search, West Grove, PA), phycoerythrin-conjugated anti–β1-integrin
(R&D Systems, Minneapolis, MN), and fluorescein isothiocyanate–
conjugated anti-CCR7 (R&D Systems). The murine CCR7 comple-
mentary DNA (cDNA) was a generous gift from Dr James Campbell
(Harvard Medical School, Boston, MA), and the human CCR7 cDNA
was fromDr RobertHromas (University ofNewMexico [UNM]Cancer
Center, Albuquerque, NM). pcDNA3.1 (Invitrogen, Carlsbad, CA) or
pEGFP-N-1 (Clontech, Mountain View) control vectors, fluorescein-
conjugated donkey antimouse (Jackson Immunoresearch), and fibronec-
tin (Sigma) were purchased.
Human Breast Cancer Tissues
Human breast cancer tissues were collected and analyzed at the UNM
with informed consent. Briefly, primary tumors were isolated, from
excess nondiagnostic tissue after either lumpectomy or mastectomy.
The tissue was resected under the supervision of UNM physician,
Donald Morris, MD, and separated into normal breast or malignant
tissue under the supervision of UNM pathologist, Nancy Joste, MD.
The tissues were prepared as described previously [9]. Briefly, minced
tissues were incubated for 16 hours at 37°C, in 0.05% rat tail collagenase
A, and large cell clumps were removed by allowing the cells to set-
tle. Selection of both normal epithelial and malignant epithelial cells
was by aMiltenyi (Miltenyi Biotech, Gladbach, Germany) magnetic sep-
arator using the anti–epithelial membrane antigen (Clone 29; Miltenyi
Biotech) antibody as the selection marker. Cells were divided into two
groups, stained with PE-conjugated anti-CCR7 (R&D Systems) or iso-
type control (R&D Systems), and analyzed by flow cytometry.
Cell Lines, Mice, and In Vivo Manipulations
PyVmT cells were generated as described [8]. MCF10A and MCF7
were purchased from ATCC (Manassas, VA). FVB/N mice were pur-
chased from Jackson Laboratories (Bar Harbor, ME). PyVmT cells were
transiently transfected using Lipofectamine Plus (Invitrogen) as per the
manufacturer’s instructions, with the following modifications: For adhe-
sion assays and in vivo injections, cells were plated at 80% density and
transfected 16 to 24 hours later with twice the suggested amount ofDNA
in serum-free Dulbecco modified Eagle medium (DMEM). Cells were
incubated in the presence ofDNA/Lipofectamine complexes for 4 hours.
Complexes were removed, cells were rinsed in prewarmed PBS, and me-
diumwas adjusted to 10% fetal bovine serum, and the cells were allowed
to recover overnight. In the morning, fresh medium was added. Cells
were transfected each evening on three consecutive days. After the final
transfection, cells were trypsinized and plated on Petri dishes overnight
at 37°C in a 5% CO2 humidified atmosphere in complete DMEM
(10% FBS/90% DMEM/2 mM L-glutamine). Cells were isolated with
light trypsin, neutralized with cDMEM, and injected into the left tho-
racic mammary fat pad of FVB/Nmice (Jackson Laboratories). Animals
were palpated for tumors starting on day 21, and length, width, and
height were measured with calipers every other day until the tumors
reached 18 mm in any measurement. At that point, the animals were
killed, and the tumors and lungs were collected and processed for his-
tology or polymerase chain reaction (PCR).
Flow Cytometry
Transfected PyVmT cells were dissociated from tissue culture with
cell dissociation solution (Sigma), rinsed three times with PBS, and la-
beled with anti-FLAG (M2) antibody (1:1000) for 1 hour on ice in
1%BSA/PBS. Cells were rinsed three times in 1%BSA/PBS and labeled
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with fluorescein-conjugated donkey antimouse (1:200) for 1 hour on
ice 1% BSA/PBS. Cells were rinsed twice in 1% BSA/PBS, resuspended
in 200 μl of 1% BSA/PBS, and assayed immediately by flow cytom-
etry (FACSCalibur; BD Bioscience, San Jose, CA).
Detection of PyVmT Expression in Lungs and Lymph Nodes
Histologic slides were blinded, examined, and scored for the presence
of metastasis by two individuals. After physical examination and isola-
tion of the lymph nodes, the DNAwas extracted using a Qiagen Tissue
Isolation Kit. DNAwas quantified; equal amounts were used to amplify
PyVmT DNA as described [8].
Chemotaxis Assay
MCF10A, MCF7, and transfected PyVmT cells were dissociated
from tissue culture with cell dissociation solution, rinsed with PBS,
and counted. Fifty thousand cells were resuspended in serum-free me-
dium added in 50 μl to the top well of a chemotaxis chamber (Neuro-
probe, Gaithersburg, MD) that had been preloaded with a 100-ng/ml
fibronectin-coated 5-μm membrane and ligand in each lower well or
serum-free medium as the control. Cells were allowed to migrate for
3 hours. At the end of the assay, the medium in the top wells was re-
moved, the chamber was disassembled, and the cells in the lower wells
were counted on a hemocytometer.
Cell Spreading Assay
Cell spreading assay was as described [10]. Briefly, PyVmT cells were
transfected 72 hours before assay with Lipofectamine Plus. Cells were
seeded in six-well dishes and transfected with either FLAG-muCCR7,
pEGFP (control to monitor transfection efficiency), or pcDNA3.1 at
2 μg of DNA per well in serum-free DMEM. At 3 hours, the medium
was adjusted to 10% FBS, and the cells were incubated overnight. The
following day, cells were rinsed in 1× Ca+2/Mg+2 free PBS and allowed
to grow for 24 hours. For MCF10A, or MCF7 cells were passaged at
least 3 days before assay and were not allowed to grow to greater than
80% confluency. On the day of the assay, the medium was aspirated,
and the cells were rinsed in Ca+2/Mg+2 free PBS, incubated in a cell
dissociation solution (Sigma), and once the cells started to detach,
the flask was rapped, and the cells were removed by pipetting. The cells
were rinsed in Ca+2/Mg+2 free PBS three times and resuspended in
serum-free DMEM + 200 mM L-glutamine. A total of 3 × 104 cells
were centrifuged at 25°C at 3000 rpm onto 13-mm coverslips that had
been preincubated with 10 μg/ml fibronectin/0.05% BSA and allowed
to spread for 4.5 hours. Cells were then fixed in 1% paraformaldehyde/
PBS. Cells were imaged using Metamorph (Molecular Devices,
Dowington, PA), and cell spreadwasmeasured. Aminimumof 100 cells
was counted per condition.
Mammosphere Cultures
Mammosphere cultures were generated as described [11]. Six million
exponentially growing PyVmT cells were isolated by trypsinization,
neutralized with complete media, and rinsed twice in PBS and electro-
porated using a Bio-Rad electroporator according to the manufacturer’s
protocol (Bio-Rad Bulletin 1349; Bio-Rad, Hercules, CA) and allowed
to recover overnight. In some cases, cells were transfected with LipoD293
(Signajen, Ijamsville, MD). Transfected cells were isolated by trypsini-
zation and rinsed twice in PBS to remove all traces of serum. For co-
cultures with primary cells, we used PyVmT-GFP that had been stably
transduced with a GFP-expressing lentivirus, pGIPZ (Thermo Scientific,
Huntsville, AL). PyVmT-GFP were then transfected with CCR7
(PyVmT-GFP-CCR7) or vector (PyVmT-GFP-pcDNA3.1) and mixed
at a 1:1 ratio with primary subinguinal lymph node or lung cells, which
had been isolated from FVBmice. Lungs wereminced with fine scissors.
Minced lung tissues and lymph nodes were dissociated by passing
through a wire mesh. Red blood cells were lysed with ACK buffer
(155 mM NH4Cl/7.2 mM KHCO3/4.8 mM EDTA) for 8 minutes
at room temperature. Cells were rinsed twice with PBS and counted. Sin-
gle cells were plated on ultra low-attachment six-well plates (Corning,
Inc, Corning, NY) at a density of 30,000 viable cells per well. Cells
were grown in serum-free mammary epithelial basal medium (Lonza,
Walkersville, MD) supplemented with 20 ng/ml EGF, 5 μg/ml insulin,
1 μg/ml hydrocortisone (Lonza), 20 ng/ml basic fibroblast growth fac-
tor, B27 (Invitrogen), 4 μg/ml heparin (MP Biomedicals, Irvine, CA),
100 IU/ml penicillin, and 100 μg/ml streptomycin (Mediatech,
Manassas, VA). Cells were fed every 3 days by addition of one-third
volume of fresh medium. Seven days after the initial plating, primary
mammospheres were measured using Metamorph. Significance of dif-
ference between PyVmT-CCR7 and PyVmT-vector control cells in
the presence or absence of ligand was determined using an unpaired
t test with the Welch correction. To assess integrin involvement, cells
were grown in the presence of 2 μg/ml anti–β1-integrin or isotype con-
trol antibodies.
Figure 1. Transient transfection of PyVmTwith N-FLAG-CCR7 results in low level of CCR7 expression. (A) PyVmTwere transiently transfected
with an N-terminally taggedmurine CCR7, dissociated from culture, stained for expression of FLAGwith anM2 antibody, counterstainedwith
fluorescein isothiocyanate–conjugated donkey antimouse, and assayed on a FACSCalibur. (B) Human CCR7 cDNA and cDNA isolated from
MDA-MB-231, MCF7, MCF10A, and T47, and human breast tumor cells and Hut78 human T cells were generated and amplified by RT-PCR.
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Results
CCR7 Is Expressed at Low Levels in Primary Human
Breast Cancers
CCR7 expression has been detected in fixed tumors [2,7,12–14].
To examine the levels of CCR7 expression on the surface of fresh
human breast cancer cells, we first isolated epithelial cells from infiltrat-
ing ductal carcinoma human breast tumor biopsy samples or from the
adjacent normal tissue. We labeled the isolated cells with anti-CCR7
antibodies (n = 6) and measured levels of CCR7 by flow cytometry.
To this end, primary epithelial cells, dissociated with collagenase were
isolated by positive selection using magnetic beads that target epithelial
cell markers. We found CCR7 elevated in three of the six patients.
Overall, there was a 46% ± 24% increase in the level of the CCR7 re-
ceptor expressed in malignant breast epithelia compared with that in
the normal tissue. Although this is a relatively low level of expression,
this increase in receptor expression levels can profoundly affect the
cellular response to ligand binding [15].
We hypothesized that low levels of CCR7 can be used by breast
cancers to metastasize to the lymph nodes to regulate cell spread, a cel-
lular function that mediates extravasation and migration. Using reverse
transcription (RT)–PCR, we determined that CCR7 is not expressed
on PyVmT cells (data not shown). Therefore, to examine the roles
of CCR7 in metastasis, we expressed CCR7 in PyVmT cells [8]. We
used a FLAG-tagged murine CCR7 to generate N-FLAG-muCCR7
expressing PyVmT (PyVmT-CCR7) transient transfectants. These
cells expressed a modest level of CCR7 that was similar to levels that
we observed in fresh tumor isolates from human breast cancer patients
(Figure 1). We used RT-PCR to confirm the expression of CCR7 in a
number of cultured human breast tumor cell lines (Figure 1).
CCR7 Regulation of β1-Integrins
Chemokines control integrin-mediated adhesion and cell spreading
[10]. Whereas adhesion promotes attachment, cell spreading is thought
to be an early step in migration. Adhesion of tumor cells through
β1-integrins promotes tumor metastasis [16]. To determine if CCR7
expression affects cell spreading through β1-integrins, we used in vitro
assays. Cover slips were coated with the β1-integrin ligand fibronectin at
10 μg/ml, and cells were allowed to adhere and spread for an hour. To
confirm specificity for the β1-integrins, we used a function blocking
β1-integrin antibody. Activation of CCR7 on PyVmT-CCR7 promoted
a significant increase in β1-integrin–specific cell spreading (Figure 2A) to
either CCL19 or CCL21. We have used flow cytometry to confirm that
MCF10A and MCF7 cells express human CCR7 ([7] and data not
shown). To determine whether CCR7 regulated cell spreading in human
cells as well, we used the MCF10A mammary cell line along with the
MCF7 human breast cancer cell line. We observed that CCR7 activation
Figure 2. CCR7 promotes cell spreading andmigration of tumor cell lines. Glass coverslips were coatedwith 10 μg/ml 0.05%BSA fibronectin
overnight. Then, 400 nM of CCL21 or CCL19 was layered on coverslips in 100 μl of serum-free media. A total of 5 × 104 (A) PyVmT-CCR7, (B)
MCF7, or (C) MCF10A cells in 100 μl of serum-free medium were plated on each coverslip and allowed to spread for 4.5 hours. Cells were
fixed, and surface areas were measured using Metamorph. Surface areas were normalized to the area of cells that had been blocked with
anti–β1-integrin antibodies and were therefore round. (D) PyVmT transfectants were allowed to migrate on fibronectin-coated 8-μm pore
membranes (10 μg/ml) for 3 hours to gradients of 40 nM CCL19 or CCL21. After 3 hours, migrated cells were counted (n = 3). (E) PyVmT
transfectants were allowed to migrate to 2, 20, 40, 80, 160, and 400 nM ligand for 3 hours through 8-μm pores, through fibronectin (10 μg/
ml)-coated membranes. After 3 hours, cells that had migrated to the bottom well of the chemotaxis chamber were counted (n = 3).
Table 1. Average Growth of Tumors In Vivo.
No. Cells Implanted Mean Days to Develop Tumor No. Animals with Tumors
1,000,000 24 6/6
100,000 24 6/6
10,000 29 2/6
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promoted cell spreading in human cell lines as well (Figure 2, B and C )
when compared with cells treated with antibodies against the β1-integrin.
After detachment from the primary tumor, an essential step in metas-
tasis is migration of cells to a second site. To determine whether CCR7
can promote migration, we used the PyVmT-CCR7, which was used in
ourmousemodel in an in vitro transwell chemotaxis assay on β1-integrin–
coated surfaces. In these assays, cells were detached from culture with
a nonenzymatic cell dissociation solution and allowed to migrate for
3 hours to CCL19 or CCL21 through fibronectin-coated polycarbonate
membranes. We found that CCR7 promoted migration to CCL19 and
CCL21 in PyVmT-CCR7 (Figure 2, D and E). From these results, we
conclude that CCR7 can promote directed migration of breast cancer
cells to lymphoid organ chemokines.
Development of a Mouse Model
To examine the physiological significance of CCR7 in cell spreading
and migration of breast cancer to CCR7 ligands, we used the PyVmT
model [8] that had been selected for metastasis preferentially to the lungs.
Previous studies, which examined the role of a different chemokine re-
ceptor, CXCR4, in metastatic behavior of tumor cells, revealed that dif-
ferences were observed between CXCR4-expressing tumors and vector
controls only when low levels of tumor cells were seeded [17]. Therefore,
to determine the lowest number of PyVmT cells that could be used to
generate tumors in the syngeneic FVB mice, we compared the numbers
of tumors generated after the introduction of 106, 105, and 104 tumor
cells. In our studies, 100% (6/6) of the animals with 106 tumor cells
developed palpable tumors within 24 days, 100% (6/6) of the animals
with 105 tumor cells developed tumors within 50 days, and 33% (2/6) of
the mice developed tumors when 104 cells were implanted (Table 1).
We injected 105 PyVmT-CCR7 or 105 PyVmT-vector (CCR7 (−))
tumor cells into the fifth mammary fat pad of FVB mice. To obtain
statistically significant data, we used 10 mice per group (Figure 3). Vol-
umes of the PyVmT-CCR7 tumors were significantly greater than the
PyVmT-vector controls during the study (Figure 3). On day 48 after
implantation, tumors in two of the PyVmT-CCR7 mice grew to sizes
greater than 18mm in a single dimension, our criterion for euthanasia,
and were immediately removed from the study. There was no signifi-
cant difference in the mean survival (P = .0842) of the mice injected
with PyVmT-CCR7 cells (75 days) when compared with the mice in-
jected with PyVmT-vector cells (58 days; Figure 3).
To determine whether CCR7 altered the metastatic behavior of
the tumors, we used PCR of isolated DNA to determine whether
PyVmT cells were present in the lymph nodes. To this end, we isolated
the draining lymph node and used half of the lymph node to isolate
DNA for PCR and used the other half for histologic preparations. By
PCR, we found that 60% of the PyVmT-CCR7 animals had PyVmT
DNA in the draining lymph nodes, contrasting with 0% of the
PyVmT-vector controls. In addition, we found that while 4 of the
10 PyVmT-CCR7 animals developed metastasis in their lungs, 100%
(10/10) of the PyVmT-vector control mice had between one and four
metastases in their lungs (Table 2). We found that there were signifi-
cantly more tumors per lung in the mice that had been injected with
PyVmT-vector control cells when compared with animals injected with
PyVmT-CCR7 cells (t test, P = .0366). Histologic sections were made,
and there were no significant differences in the appearance of the lymph
nodes between the two groups of animals (Figure 4).
To determine the contribution of CCL19 and CCL21 to differences
in growth between PyVmT-CCR7 and PyVmT-vector control animals,
we used measured growth in tissue culture. We found that, when cells
were grown in tissue culture, there was no statistically significant dif-
ference in the rates of proliferation of CCR7 expressing cells (Figure 5).
Breast cancer cells can grow in three dimensions as mammospheres
[18]. To determine whether CCR7 promoted growth under conditions
that allow three-dimensional proliferation of PyVmT,we used amammo-
sphere assay. To this end, we grew PyVmT-CCR7, PyVmT-vector,
± (CCL21), or (CCL19) in three dimensions [11]. Althoughwe observed
a dose-dependent response on the size of the mammospheres grown in
the presence of ligand when compared with the PyVmT-vector controls,
which mirrored the increased growth rate of the PyVmT-CCR7 that we
observed in our FVB mice in vivo (Figure 5 and Table 2), we found no
significant difference in the number of mammospheres generated. Be-
cause growth in the presence of CCL19 was greater than with CCL21,
we examined the growth of MCF7 and MCF10A cells in response to in-
creasing concentrations of CCL19. We observed that CCL19 promoted
Figure 3. PyVmT-CCR7 tumor volumes are significantly larger than tumors derived from PyVmT-vector control cells. (A) A total of 105 cells
were injected into the fifthmammary fat pad of FVBmice. Palpable tumorswere detected as early as day 25 in both groups. Tumors growth
as measured with calipers (length × width × height). (B) At day 48, the average tumor volume of PyVmT-CCR7 tumors (259.9 ± 71.22)
was significantly larger than the PyVmT-vector controls (119.1 ± 27.30), Student t test, P = .002. (C) Survival curve for mice injected with
PyVmT-CCR7 tumors (CCR7+) versus PyVmT-vector controls.
Table 2. Metastatic Targets of PyVmT Tumors In Vivo.
Observed Differences in Mice Injected Orthotopically with PyVmT-CCR7 or PyVmT-Vector
Control Cells
Cell Line Animals with Tumors in Lung
(Average Number of Tumors)
Presence of PyVmT in Lymph
Node by PCR
PyVmT-CCR7 4/10 6/10
PyVmT-vector 10/10 0/10
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growth of all three cell lines. From these studies, we conclude that CCR7
can regulate the growth of tumor cells.
CCR7-expressing cells may show preferential migration to or
preferential proliferation within lymph nodes. Although PyVmT cells
migrate to CCR7 ligands, it was important to determine whether
PyVmT-CCR7 cells grow more efficiently in the presence of lymph
node cells than lung cells. To this end, we used mammosphere assays.
To be able to discriminate between PyVmT cells and primary lung or
lymph node tissues, we used PyVmT that had been stably transduced
with GFP (Figure 6). PyVmT-CCR7 or PyVmT-vector controls were
grown in the presence of equal ratios (1:1) of lymph node or lung cells.
The presence of primary cells from either the lung or the lymph nodes
had no effect on the proliferation of PyVmT-vector cells (Figure 7). In
contrast, whereas PyVmT-CCR7 were able to grow in the presence of
lymph node tissues, there was a significant (P = .0036) reduction in
the average size of PyVmT-CCR7 mammospheres formed in the pres-
ence of lung tissue. We conclude that when PyVmTexpress CCR7, the
cells grow less efficiently in the presence of lung tissues, where CCR7
ligands are scarce.
Because CCR7 promotes activation of β1-integrins and integrins are
important ligands in mediating entry into lymph nodes, we examined
the effects of inhibiting β1-integrins on three-dimensional culture pro-
liferation (Figure 8). We observed that in the presence of β1-integrin
function–blocking antibodies and CCL19, cells proliferated at the
same rate as the controls that were not grown in the presence of
CCL19. There was no significant reduction in the growth rate of
three-dimensional cultures in the presence of isotype antibodies, when
compared with untreated controls. We conclude that PyVmT-CCR7
grows more efficiently when allowed to adhere and grow in the pres-
ence of CCR7 ligands.
Discussion
We have established a CCR7-expressing mouse model of breast cancer
metastasis that allowed us to examine the roles of CCR7 in breast can-
cer progression and metastasis both in vivo and in vitro. Similar to
what has been observed in cancer patients, CCR7 can control targeting
of tumor metastases in vivo. In addition, we found that CCR7 func-
tions through β1-integrins to induce cell spread and migration in both
human and murine breast cancers. In this way, CCR7 directs PyVmT-
CCR7 cells to the lymph nodes in vivo, whereas CCR7-expressing
tumors are inhibited in generating lung metastasis.
In clinical studies, the spread of CCR7-expressing breast tumors and
bone metastasis was restricted to the surgically removable lymphoid
Figure 4. Significantly more PyVmT tumors grew within the lungs
when compared with PyVmT-CCR7, but there was no difference
in lymph node morphology. (A) A total of 105 cells were injected into
the fifthmammary fat pad of FVBmice. Once tumors reached 18mm
in any dimension, the animalswere killed, the lungswere fixed in buff-
ered formalin, and tumors were enumerated. (B) Draining lymph
nodes were removed, fixed in buffered formalin, and cut in half and
used to generate DNA for PCR or stainedwith hematoxylin and eosin.
Figure 5. Stimulation of CCR7 does not affect proliferation of PyVmT tumors in two-dimensional tissue but controls growth in three-
dimensional tissue. (A) A total of 105 PyVmT-CCR7 cells were allowed to grow ± 40 nM ligand on tissue culture plates for the indicated
periods. Cells were trypsinized and counted in duplicate. Results are means ± SD (n = 3). (B) Mean size of PyVmT mammospheres in
40 nM ligand. (C) Mean number of PyVmT mammospheres in 40 nM ligand per 10× field. (D) PyVmT, (E) MCF10A, or (F) MCF7 volume
of mammospheres relative to PBS controls at the indicated concentrations of CCL19 ligand. Mammospheres were imaged by Meta-
morph, and sizes were measured or numbers of mammospheres were counted (n = 5).
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organs [14]. Without an animal model, it has remained difficult to
identify the cellular mechanisms that result in targeting metastasis from
the mammary fat pad to the lymph nodes. From our studies, we find
that CCR7 expression leads to increased β1-integrin–mediated tumor
growth and promotes tumor migration to the lymph nodes. We found
that both PyVmT-CCR7 and the CCR7-expressing breast cancer cell
line MCF7 grew significantly larger mammospheres compared with
vector controls. Proliferation of MCF7 and MCF10A increased in a
dose-dependent manner in the presence of CCL19. Importantly, we
found that in the lung, PyVmT grew more efficiently in the absence
of CCR7. It is unclear to what extent CCR7 prevents cell death or pro-
motes proliferation, although recently, it has been shown that CCR7
prevents anoikis of MDA-MB-231, MDA-MB-361, and MDA-MB-
453 cancer cells; mediates activation of mitogen-activated protein kinases
[19,20]; promotes [21] proliferation of B-cell lymphocytic leukemias;
and blocks apoptosis in hematopoietic cells [22–24]. Whereas CCR7
had been shown to prevent apoptosis before our study [24], it had not
been implicated in enhancing breast tumor growth or regulating breast
tumor proliferation in a tissue-specific manner. Although we found that
PyVmT-CCR7 mammospheres grew at different rates than vector con-
trols, it will be important to use thesemammospheres in future biochem-
ical assays to further our understanding of the mechanisms used by
CCR7 in breast cancer cells to control the extent of tumor growth in
different tissues in the body.
Activation of β1-integrins in breast tumor cells is linked to in-
creased proliferation [16]. Although CCR7 has been found to regulate
lymphocyte-specific integrins such as LFA-1 in T cells because breast
cancer tumor cells do not express the LFA-1, it was unclear to what
extent CCR7 could regulate the β1-integrins. We found that in CCR7-
expressing PyVmT,CCL19 andCCL21 promote β1-integrin–mediated
cell spread, migration, and proliferation in both human and murine
cell cultures. However, human and murine tumors migrate differently
on fibronectin-coated membranes to the two CCR7 ligands. Whereas
PyVmT-CCR7 migrates preferentially to CCL19, MCF10A and MCF7
migrate to CCL21. We and others have shown that T cells differentially
regulate desensitization of CCR7 [25,26]. It is unclear if breast tumor
cells respond differently to regulate signaling fromCCL19 and CCL21,
and our future studies will focus on understanding mechanisms used
by human and mouse tumor cells to desensitize signaling through
CCR7 in response to CCL21 and CCL19.
Because the PyVmT cell line used in this study metastasizes pri-
marily to the lung [8], we hypothesized that expression of CCR7 would
increase migration of breast cancer cells to the lymph nodes. Because
Figure 6. PyVmT-GFP-CCR7mammospheres grow at different rates
in the presence of primary lung and lymph node cells. PyVmT-GFP
cells were transiently transfected with CCR7 or pcDNA3.1 andmixed
at a 1:1 ratio with subinguinal lymph node or lung cells. Cells were
allowed to form mammospheres on low adhesion plates for 7 days,
fixed in 1% paraformaldehyde, and then imaged and measured
using Metamorph.
Figure 7. PyVmT-CCR7 mammospheres grow more efficiently in
the presence of lymph node tissues than in the presence of lung
tissues. PyVmT-GFP cells were transiently transfected with CCR7
or pcDNA3.1 and mixed at a 1:1 ratio with subinguinal lymph node
or lung cells. Cells were allowed to form mammospheres on low-
adhesion plates for 7 days, fixed in 1% paraformaldehyde, and then
imaged and measured using Metamorph.
Figure 8. Adhesion through the β1-integrins mediates proliferation
of three-dimensional cultures. MCF7 were allowed to grow in low-
adhesion plates at 40 nM CCL19 ligand in the presence of function-
blocking β1-integrin antibodies or isotype control. Mammospheres
were imaged by Metamorph, and sizes were measured or numbers
of mammospheres were counted (n = 3).
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the presence of lymph node metastasis correlates with a poor prognosis,
we expected that increased migration of breast cancer cells to lymph
nodes would lead to increased migration of PyVmT-CCR7 tumors in
the lungs. However, it is important to bear in mind that the function
that lymph nodes play in the development of cancer is unknown, and
we have considered several possibilities. If the lymph nodes serve as
filters to trap escaped tumor cells, we would expect to find lymph node
metastasis in both PyVmT-CCR7 and PyVmT-vector control mice. We
found lymph node metastasis only in the PyVmT-CCR7 mice, which
implicates CCR7 in actively directing metastasis to the lymph nodes.
We also found that CCR7-expressing PyVmT cells did not grow well in
the presence of lung tissue, when compared with lymph node tissue co-
culture (Figures 6 and 7). In addition, we found significantlymore tumors
per mouse in the lungs of animals injected with PyVmT-vector (Figure 4)
when compared with the animals injected with PyVmT-CCR7. We did
observe that blocking β1-integrin adhesion reduced proliferation of the
human MCF7 breast cancer mammospheres (Figure 8). That CCR7
actively targets migration to and promotes proliferation of PyVmT
within the lymph nodes and less efficiently to the lungs in both humans
and mice will allow us to use our model to better understand the devel-
opment of metastatic breast cancer to different sites in the body.
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